"uuid:ID","name","instanceType","id","description","rationale","label"
"72b5492a-3932-4a98-8679-0784b020f13e","Study Design 1","StudyDesign","StudyDesign_1","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.",""
